AJTMH HINARI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 58(1), 1998, pp. 17-21
Copyright © 1998 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vanhauwere, B
Right arrow Articles by Kerr, L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vanhauwere, B
Right arrow Articles by Kerr, L
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*MEFLOQUINE
Related Collections
Right arrow Malaria
Right arrow Plasmodium
American Journal of Tropical Medicine and Hygiene, Vol 58, Issue 1, 17-21
Copyright © 1998 by American Society of Tropical Medicine and Hygiene

Research Articles


Post-marketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy

B Vanhauwere, H Maradit, and L Kerr

The purpose of this study was to evaluate the teratogenic potential of mefloquine (Lariam) in pregnancy, based on the Roche International Spontaneous Reporting System. Lariam is an anti-malarial drug used both in prophylaxis and treatment of malaria. Teratogenic effects were observed in animals but data from humans are lacking. Women of childbearing potential are currently advised to take contraceptive precautions up to three months after the last dose. The study included 1,627 spontaneous reports of women exposed to Lariam before or during pregnancy, which were received by Roche worldwide since introduction on the market. The data were analyzed considering pregnancy and fetal outcome and type of congenital malformations. The birth prevalence of congenital malformations in women exposed to Lariam is estimated to be 4% and is not different from the prevalence observed in the general population. In addition, the congenital malformations observed with Lariam exposure do not show any specific pattern. The data from our study suggest that the teratogenicity, which was observed in animals at high doses, cannot be applied to humans.


This article has been cited by other articles:


Home page
 NEJMHome page
D. O. Freedman
Malaria Prevention in Short-Term Travelers
N. Engl. J. Med., August 7, 2008; 359(6): 603 - 612.
[Full Text] [PDF]

Home page
 JAMAHome page
K. S. Griffith, L. S. Lewis, S. Mali, and M. E. Parise
Treatment of Malaria in the United States: A Systematic Review
JAMA, May 23, 2007; 297(20): 2264 - 2277.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
M. Barry
Primaquine Prophylaxis against Malaria
Ann Intern Med, March 16, 1999; 130(6): 536 - 536.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Society of Tropical Medicine and Hygiene.